Repros Therapeutics (RPRX) Reaches $0.40 52-Week Low, 6 Analysts Covering Valeant Pharmaceuticals Intl (VRX)

July 17, 2017 - By Vivian Currie

The stock of Repros Therapeutics Inc (NASDAQ:RPRX) hit a new 52-week low and has $0.37 target or 7.00% below today’s $0.40 share price. The 7 months bearish chart indicates high risk for the $11.53 million company. The 1-year low was reported on Jul, 17 by Barchart.com. If the $0.37 price target is reached, the company will be worth $807,100 less. About 5.17 million shares traded or 411.88% up from the average. Repros Therapeutics Inc (NASDAQ:RPRX) has declined 73.82% since July 17, 2016 and is downtrending. It has underperformed by 90.52% the S&P500.

Among 25 analysts covering Valeant Pharmaceuticals Intl (NYSE:VRX), 6 have Buy rating, 3 Sell and 16 Hold. Therefore 24% are positive. Valeant Pharmaceuticals Intl had 107 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by RBC Capital Markets on Tuesday, November 3 with “Outperform”. As per Monday, November 2, the company rating was maintained by Jefferies. The firm has “Hold” rating by RBC Capital Markets given on Friday, June 16. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has “Buy” rating given on Wednesday, June 28 by Cantor Fitzgerald. The stock has “Buy” rating by Jefferies on Wednesday, March 16. The firm earned “Buy” rating on Monday, April 11 by Rodman & Renshaw. The firm earned “Buy” rating on Wednesday, March 16 by Rodman & Renshaw. The company was reinitiated on Wednesday, January 6 by Susquehanna. Stifel Nicolaus maintained Valeant Pharmaceuticals Intl Inc (NYSE:VRX) on Wednesday, November 11 with “Buy” rating. The stock of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) earned “Sector Perform” rating by IBC on Tuesday, October 20. See Valeant Pharmaceuticals Intl Inc (NYSE:VRX) latest ratings:

12/07/2017 Broker: Piper Jaffray Rating: Sell New Target: $10.0000 Maintain
29/06/2017 Broker: Stifel Nicolaus Rating: Buy New Target: $35.0000 Maintain
28/06/2017 Broker: Cantor Fitzgerald Rating: Buy New Target: $23.0000 Maintain
19/06/2017 Broker: Wells Fargo Rating: Sell
16/06/2017 Broker: RBC Capital Markets Rating: Hold New Target: $19.0000 Maintain
16/06/2017 Broker: Guggenheim Rating: Buy New Target: $18.0000 Initiate
09/06/2017 Broker: Jefferies Rating: Buy New Target: $18.0000 Maintain
08/06/2017 Broker: Canaccord Genuity Rating: Hold New Target: $14.0000 Maintain
08/06/2017 Broker: BMO Capital Markets Rating: Hold New Target: $15.0000
20/06/2017 Broker: Mizuho Rating: Underperform New Target: $8.00 Maintain

Since March 13, 2017, it had 3 buys, and 1 sale for $166.26 million activity. $199.26M worth of Valeant Pharmaceuticals Intl Inc (NYSE:VRX) was sold by Pershing Square Capital Management – L.P.. On Tuesday, March 14 the insider ValueAct Holdings – L.P. bought $32.47 million. 24,000 shares valued at $257,280 were bought by Herendeen Paul on Tuesday, March 14. Another trade for 20,000 shares valued at $278,000 was bought by DE SCHUTTER RICHARD U.

About 9.64M shares traded. Valeant Pharmaceuticals Intl Inc (NYSE:VRX) has declined 48.51% since July 17, 2016 and is downtrending. It has underperformed by 65.21% the S&P500.

Investors sentiment decreased to 0.78 in 2016 Q4. Its down 0.10, from 0.88 in 2016Q3. It worsened, as 82 investors sold Valeant Pharmaceuticals Intl Inc shares while 87 reduced holdings. 49 funds opened positions while 82 raised stakes. 193.03 million shares or 13.22% less from 222.43 million shares in 2016Q3 were reported. Valley Advisers holds 99 shares. Pomelo Cap Limited Liability stated it has 0.29% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Winslow Evans & Crocker owns 2,000 shares or 0% of their US portfolio. First Eagle Inv Mngmt Limited Com holds 613,800 shares or 0.02% of its portfolio. Moreover, Hap Trading Ltd Limited Liability Company has 0.94% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 1.29M shares. Bb&T Ltd Liability Corp, Virginia-based fund reported 27,595 shares. Riverpark Advsrs Lc, New York-based fund reported 14,995 shares. Saba Cap Management Lp has invested 1.47% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Academy Cap Management Inc Tx stated it has 2.12% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Manufacturers Life Ins Com The stated it has 0.02% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Next Fincl Group Inc accumulated 3,992 shares. Scepter Hldg Inc stated it has 500,000 shares or 5.88% of all its holdings. Moreover, Jones Collombin Counsel has 0.08% invested in Valeant Pharmaceuticals Intl Inc (NYSE:VRX) for 16,485 shares. Stifel Financial Corporation has invested 0.01% in Valeant Pharmaceuticals Intl Inc (NYSE:VRX). Balyasny Asset Ltd Com stated it has 1.49 million shares.

Valeant Pharmaceuticals International, Inc. is a pharmaceutical and medical device company. The company has market cap of $5.99 billion. The Firm is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices). It currently has negative earnings. It operates through two divisions: Developed markets and Emerging markets.

Among 3 analysts covering Repros Therapeutics (NASDAQ:RPRX), 1 have Buy rating, 1 Sell and 1 Hold. Therefore 33% are positive. Repros Therapeutics had 5 analyst reports since August 20, 2015 according to SRatingsIntel. Ladenburg Thalmann downgraded the shares of RPRX in report on Friday, October 30 to “Neutral” rating. The firm has “Underperform” rating by Bank of America given on Friday, October 30. The firm has “Hold” rating given on Thursday, August 20 by Zacks. The stock has “Hold” rating by Brean Capital on Friday, October 30. The firm has “Buy” rating by Ladenburg Thalmann given on Wednesday, November 16.

Investors sentiment decreased to 0.88 in Q4 2016. Its down 0.20, from 1.08 in 2016Q3. It dropped, as 8 investors sold Repros Therapeutics Inc shares while 8 reduced holdings. 4 funds opened positions while 10 raised stakes. 6.56 million shares or 1.15% more from 6.48 million shares in 2016Q3 were reported. California Pub Employees Retirement Systems holds 118,000 shares. Manufacturers Life Ins The invested in 0% or 1,321 shares. State Street holds 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX) for 13,551 shares. Blackrock Fund accumulated 60,822 shares. Jacobs Levy Equity Mngmt Incorporated holds 268,130 shares or 0.01% of its portfolio. Savings Bank Of Montreal Can holds 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX) for 1,000 shares. Baldwin Brothers Ma stated it has 0% in Repros Therapeutics Inc (NASDAQ:RPRX). Vanguard Grp holds 0% or 882,436 shares. Comml Bank Of America De stated it has 0% of its portfolio in Repros Therapeutics Inc (NASDAQ:RPRX). Connor Clark And Lunn Investment Limited owns 37,700 shares or 0% of their US portfolio. Susquehanna Grp Llp reported 71,827 shares stake. Blackrock Inv Llc holds 0% in Repros Therapeutics Inc (NASDAQ:RPRX) or 3,757 shares. Goldman Sachs Grp, a New York-based fund reported 18,145 shares. 343 are owned by Tower Rech Cap Limited Liability Co (Trc). Benjamin F Edwards & Inc has 0% invested in Repros Therapeutics Inc (NASDAQ:RPRX) for 2,700 shares.

Repros Therapeutics, Inc. is a biopharmaceutical firm focused on the development of new drugs to treat hormonal and reproductive system disorders. The company has market cap of $11.53 million. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. It currently has negative earnings. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.